NVO logo

NOVO-NORDISK A/S-SPONS ADR

NVONYSE
🏆 #88 by market capEarnings Nov 4US Equity
$38.29▼ $0.38 (−0.98%)
🌙 After hours$38.11▼ 0.46%Regular close · extended-hours price shown
🔔
Track NVO
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 1.0%
7d▼ 2.9%
14d▼ 2.4%
30d▼ 0.1%
ytd▼ 24.7%
1y▼ 25.5%
🏦Market Cap
$168.93B
Mid Cap
📈Revenue Growth (YoY)
6.4%
Slowing
📊Gross Margin
80.7%
High
💵FCF Margin
14.8%
Healthy
⚖️P/S Ratio
3.4x
Fair
Otter Score
72
Strong

Trading Snapshot

Day Range
$37.96 – $38.54
52-Week Range
$35.12 – $64.16
Volume (shares)
11,346,231
Avg Volume (shares)
—
Shares Outstanding
4.41B
Next Earnings
2026-11-04

Fundamentals Snapshot

Annual Revenue
$309.06B
Last Q Revenue
$78.49B
P/E Ratio
9.7
P/S Ratio
3.4x
EPS (TTM)
$26.30
Dividend Yield
4.59%
Dilution (1yr)
−0.3%
NVO logo

NOVO-NORDISK A/S-SPONS ADR

NVO
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$309.1B▲ +6.4% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
81.0%▼ −4.4% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$127.7B▼ −0.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$29.0B▼ −58.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
4.45B▼ −0.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$104.5B▼ −$17.4B YoY
StockOtter · stockotter.space

About NOVO-NORDISK A/S-SPONS ADR

Pharma with leading GLP-1 franchise (Ozempic, Wegovy).

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Strong
72/100

Analyst Ratings

ⓘ
Consensus
Hold
35 analysts
Strong Buy4
Buy6
Hold21
Sell3
Strong Sell1
Ratings as of Oct 2026

Latest News & Updates

24/7 Wall Street·9h ago

16% of Employers Are Thinking About Cutting Weight-Loss Drug Coverage

Employers are quietly reconsidering who foots the bill for GLP-1 weight-loss drugs, and the fallout hits Eli Lilly and Novo Nordisk very differently heading into earnings week.

Zacks Investment Research·1d ago

Novo Nordisk (NVO) Stock Declines While Market Improves: Some Information for Investors

In the latest trading session, Novo Nordisk (NVO) closed at $38.7, marking a -1.11% move from the previous day.

Seeking Alpha·1d ago

Novo Nordisk Vs. Eli Lilly Q3 Preview: I'd (Now) Buy Both, But Lilly Is My Top Pick

Eli Lilly and Company has decisively outpaced Novo Nordisk A/S in the GLP-1/obesity/T2D market, now commanding a $1.21T valuation. NVO's share price has retraced all post-Wegovy gains; revenue growth is stagnant, but man

The Motley Fool·1d ago

Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026?

Amgen maintains a robust presence in oncology and rare diseases with a 9.9% revenue growth rate in FY 2025. Novo Nordisk continues to dominate the global diabetes and obesity markets with a high net margin of 33.1%.

Defense World·1d ago

Novo Nordisk A/S $NVO Stock Sold by Evergreen Capital Management LLC

Evergreen Capital Management LLC decreased its holdings in Novo Nordisk A/S (NYSE: NVO) by 15.7% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Comm

Globe News Wire·2d ago

Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades

DENVER, Oct. 26, 2026 (GLOBE NEWSWIRE) -- (247marketnews. com) - Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), AstraZeneca (NYSE: AZN), and Roche (OTCQX: RHHBY) are among the biopharma companies committing billions of